peac-logo

Mission: The Patients Equal Access Coalition (PEAC) is a patient focused coalition of  organizations representing patients, health care professionals, care centers, and industry collaboratively joined together to ensure that cancer patients have equality of access (and equality of insurance coverage) to all approved anticancer regimens including, but not limited to oral and intravenous drugs, injections, surgery, radiation, transplantation, etc. PEAC believes that every cancer patient should have access to the anticancer regimens recommended by their physicians and should not suffer from cost discrimination based on the type of therapy provided or the mechanism of delivery.

Area of Focus: Equal reimbursement parity for anticancer regimens regardless of delivery method including, but not limited to oral and intravenous drugs, injections, surgery, radiation, transplantation, etc.

Goals of the Coalition:

  1.  Ensure that all major stakeholders (patients, non-cancer orgs, providers, industry, etc.)  are represented in some way.
  2.  Ensure that access to anticancer regimens regardless of delivery method is maintained and patients don’t have to forgo taking their medication because of the expense.
  3.  Educate policymakers at all levels about the impact of disparities in anticancer regimens reimbursement
  4.  Raise visibility of this issue in Congress through activities such as Congressional briefings and hearings.
  5.  Ensure that a federal bill is enacted as a “floor” so that more patient friendly state laws are not preempted.
  6.  Ensure that federal legislation does not contain loopholes with unintended consequences for the patient. Federal legislation should include provisions such as:
    •  A patient’s out of pocket costs related to coverage for orally administered chemotherapy shall be on a basis no less favorable than current coverage provided for intravenously administered or injected chemotherapy under the policy.
    •  A health insurer cannot achieve compliance with this section by imposing an increase in patient out of pocket costs with respect to intravenously administered or injected chemotherapy agents covered under the policy on the effective date of the legislation.
    • Nothing herein shall be interpreted to prohibit a health insurer from requiring prior authorization or imposing other appropriate utilization controls in approving coverage for any chemotherapy.
  7. Ensure that progress continues at the state level on these issues.

We would love to hear from you.  Please fill out the form below and we would get back to you as soon as we can.